Treatment with both SID peptide and avermectins [16] targets multiple key genes in the EMT pathway, including TGFB1, and it is noteworthy that inhibition of TGFβ activity has been associated with loss of KDM5B in basal-like breast cancer cells [30]. Here, TGFB1 is linked to breast carcinoma.